Table of Contents Table of Contents
Previous Page  982 / 1119 Next Page
Information
Show Menu
Previous Page 982 / 1119 Next Page
Page Background

BENEFIT FROM CONCOMITANT RADIOCHEMOTHERAPY

AUTHOR

RANDOMISATION ARMS

STAGE

LOCOREGIONAL

RECURRENCE

3 YEAR OVERALL

SURVIVAL

Keys

et al

N Engl J Med.

1999

RT + Cisplatin + HE

RT+ HE

Bulky

IB

9%

21%

RR 0.51 (95% CI)

83%

74%

(p=0.008)

Whitney

et al

J Clin Oncol. 1999

RT + Cis/5-FU

RT + HU

IIB,III,

IVA

24.9%

30.4%

RR 0.79 (90% CI)

67%

57%

(p=0.018)

Rose

et al

N Engl J Med.

1999

RT + Cisplatin

RT + Cis/5-FU+HU

RT + HU

IIB,III,

IVA

Not reported

65%

65%

47%

(p=0.004)

Morris

et al

N Engl J Med.

1999

RT + Cis/5-FU

RT (pelvis + paraaortal)

IB-IVA

(~70%

IB-IIB in

each

group)

19%

35%

RR 0.47 (95% CI)

75%

63%

(p=0.004)

Peters

et al

J Clin Oncol. 2000

HE + RT + Cis/5-FU

HE + RT

IA2,IB,

IIA

5.5%

17%

81%

71%

(p=0.007)

Pearcey

et al

J Clin Oncol. 2002

RT+Cisplatin

RT

IB-IVA

Not reported

69%

66%

(p=0.42)

SURVIVAL AND RECURRENCE AFTER CONCOMITANT

CHEMOTHERAPY AND RADIOTHERAPY FOR CANCER OF UTERINE

CERVIX: A SYSTEMATIC REVIEW AND META-ANALYSIS

Green et al. Lancet 2001;358:781-86

RT

RCHT

LOCAL RECURRENCE RATE

WAS SIGNIFICANTLY REDUCED BY CHEMORADIATION

OR 0.61, 95% CI 0.51-0.73, p< 0.0001

8%

4%

16%

9%

Toxicity Grade 3-4

Haematological

Gastrointestinal

47%

63%

PFS

40%

52%

OS

3656 patients (19 studies)